Treatment Algorithms: Prostate Cancer
Prostate cancer is one of the ‘big four’ tumor types (along with breast cancer, lung cancer and colorectal cancer), and is the second most common cancer in males. Datamonitor estimates that 532,900 men were diagnosed with prostate cancer in the seven major markets (the US, Japan, France, Germany, Italy, Spain and the UK) in 2011 alone
The overall 5-year relative survival of prostate cancer patients is approximately 99.4%. The 10 and 15-year survival rates are approximately 93% and 77% respectively, although stage at diagnosis influences overall prognosis.
Physicians must take administration route, overall survival, and progression-free survival benefits as well as cost into consideration when deciding between use of Zytiga (abiraterone; Johnson&Johnson), Jevtana (cabazitaxel; Sanofi) and Provenge (sipuleucel-T; Dendreon).
Request a Sample for or Inquire before buying the report@ http://www.reportsnreports.com/reports/144316-treatment-algorithms-prostate-cancer.html
Your key questions answered
- Understand how the dynamics of prostate cancer treatment are changing as a result of three recent drug approvals
- Analyze country, treatment and drug specific prescribing rates of prostate cancer drugs across the seven major markets
- Gain insight into the percentage of patients receiving new therapies gauging perspective into potential population sizes for pipeline drugs
Major points covered in Table of Contents of this report include
- OVERVIEW
- EXECUTIVE SUMMARY
- METHODOLOGY
- DISEASE DEFINITION AND DIAGNOSIS
- PATIENT SEGMENTATION
- CURRENT TREATMENT OPTIONS
- BIBLIOGRAPHY
- APPENDIX A
Explore Comprehensive list of more than 102 Tables & Figures available in the report Treatment Algorithms: Prostate Cancer
No comments:
Post a Comment